You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 14, 2025

Details for Patent: 10,933,090


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,933,090 protect, and when does it expire?

Patent 10,933,090 protects VELPHORO and is included in one NDA.

Protection for VELPHORO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has ninety-three patent family members in thirty-four countries.

Summary for Patent: 10,933,090
Title:Pharmaceutical compositions
Abstract: Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
Inventor(s): Weibel; Ludwig Daniel (Waldstatt, CH), Philipp; Erik (Arbon, CH)
Assignee: Vifor Fresenius Medical Care Renal Pharma Ltd (St. Gallen, CH)
Application Number:16/932,124
Patent Claim Types:
see list of patent claims
Composition; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,933,090: A Comprehensive Analysis

Introduction

Patent 10,933,090, like any other patent, is a complex document that requires a thorough understanding of its scope, claims, and the broader patent landscape. This analysis will delve into the key aspects of this patent, including the evaluation of its claims, the role of recent USPTO guidance, and the implications for innovators and patent practitioners.

Patent Claims and Scope

Independent Claim Length and Count

The scope of a patent is often measured by the length and count of its independent claims. Research has shown that these metrics can provide insights into the breadth and clarity of the patent. For instance, narrower claims at publication are associated with a higher probability of grant and a shorter examination process compared to broader claims[3].

Claim Structure and Eligibility

Patent claims must be carefully crafted to ensure they meet the eligibility criteria under 35 U.S.C. § 101. This involves ensuring that the claims do not cover abstract ideas, laws of nature, or natural phenomena without a practical application. The 2024 USPTO guidance update emphasizes the importance of integrating judicial exceptions into practical applications to make the claims patent-eligible. For example, if a claim specifies the use of separated audio components in a speech recognition system to improve voice command accuracy, it adds a level of practical utility that makes the claim eligible[1].

Evaluating Patent Eligibility

The Two-Stage Framework

The Supreme Court has established a two-stage framework for evaluating patent eligibility under § 101. The first stage involves determining whether the claim is directed to a judicial exception (e.g., abstract idea, law of nature, natural phenomenon). If it is, the second stage assesses whether the claim elements, both individually and as an ordered combination, transform the nature of the claim into a patent-eligible application[5].

Practical Application and Technological Improvement

The 2024 USPTO guidance highlights the need to evaluate whether a claim integrates a judicial exception into a practical application. This involves assessing additional elements in the claim to determine if they impose meaningful limits on the exception, thereby transforming the claim into patent-eligible subject matter. This step is crucial in determining whether the claimed invention offers a concrete technological improvement[1].

AI-Assisted Inventions

Role of AI in Patent Eligibility

The method of invention development, including the use of AI, does not impact the subject matter eligibility of the patent. The focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies. This distinction is important as it ensures that AI’s role as a tool does not exclude inventions from eligibility, provided there is significant human contribution[1].

Determining Inventorship

True and Only Inventors

US patent law stipulates that only the true and only inventors are entitled to a patent. Determining inventorship involves a two-step process: the conception of the idea and the reduction of the idea to practice. Incorrect or incomplete identification of inventors can lead to challenges and potentially render the patent unenforceable[2].

Patent Term Adjustments and Obviousness

Patent Term Adjustments

Patent term adjustments (PTA) can extend the term of a patent due to delays in the patent office's response times. However, these adjustments do not extend the term past the date of a terminal disclaimer. The analysis of obviousness (ODP) must consider the adjusted expiration date of the patent, including any PTA granted[4].

Obviousness and Terminal Disclaimers

The Court of Appeals for the Federal Circuit has clarified that ODP analyses should be based on the expiration date of the patent, including any PTA. Terminal disclaimers, which are often used to overcome ODP rejections, should also be considered in this context. This ensures that an inventor cannot secure a second, later-expiring patent for an invention covered by a patent with a different term due to PTA[4].

Case Law and Precedents

Electric Power Group, LLC v. Alstom S.A.

In this case, the Federal Circuit affirmed a district court's summary judgment that certain patent claims failed the tests for patent eligibility under § 101. The claims were deemed too broad and did not limit themselves to technical means for performing the functions, which are arguably an advance over conventional technology[5].

Practical Implications for Innovators and Patent Practitioners

Ensuring Patent Eligibility

Innovators and patent practitioners must ensure that their claims are carefully drafted to integrate judicial exceptions into practical applications. This involves specifying the use of the invention in a concrete technological context to avoid eligibility issues.

Utilizing AI in Invention Development

AI can be a powerful tool in the invention development process, but it is crucial to maintain significant human contribution to ensure the invention remains eligible for patent protection.

Accurate Inventorship Determination

Correctly identifying the true and only inventors is vital to avoid potential challenges and ensure the enforceability of the patent.

Key Takeaways

  • Patent Claims and Scope: Narrower claims are associated with a higher probability of grant and shorter examination processes.
  • Patent Eligibility: Claims must integrate judicial exceptions into practical applications to be eligible.
  • AI-Assisted Inventions: AI’s role as a tool does not exclude inventions from eligibility if there is significant human contribution.
  • Inventorship: Correct identification of true and only inventors is crucial for patent enforceability.
  • Patent Term Adjustments: ODP analyses must consider the adjusted expiration date of the patent, including any PTA.

FAQs

What is the significance of the 2024 USPTO guidance update on AI patent eligibility?

The 2024 USPTO guidance update clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring AI-assisted inventions are evaluated equally with other technologies.

How do patent term adjustments affect the analysis of obviousness?

Patent term adjustments (PTA) must be considered in the analysis of obviousness (ODP), and any ODP analysis should be based on the adjusted expiration date of the patent, including any PTA granted.

What are the key steps in determining inventorship for a US patent application?

Determining inventorship involves a two-step process: the conception of the idea and the reduction of the idea to practice. It is crucial to identify the true and only inventors to ensure the patent remains enforceable.

How does the two-stage framework for evaluating patent eligibility under § 101 work?

The first stage involves determining whether the claim is directed to a judicial exception. If it is, the second stage assesses whether the claim elements transform the nature of the claim into a patent-eligible application.

What metrics can be used to measure the scope of a patent?

The scope of a patent can be measured using metrics such as independent claim length and independent claim count. These metrics provide insights into the breadth and clarity of the patent.

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. Determining Inventorship for US Patent Applications - Oregon State University
  3. Patent Claims and Patent Scope - SSRN
  4. In re Cellect - United States Court of Appeals for the Federal Circuit
  5. Electric Power Group, LLC v. Alstom S.A. - United States Court of Appeals for the Federal Circuit

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,933,090

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vifor Fresenius VELPHORO ferric oxyhydroxide TABLET, CHEWABLE;ORAL 205109-001 Nov 27, 2013 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,933,090

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07120837Nov 16, 2007

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.